Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ppi-1011
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mld's PPI-1011 Shows Positive Phase 1 Results as Synthetic Plasmalogen Precursor
Details : PPI-1011 is a synthetic plasmalogen precursor being developed as a treatment for diseases of plasmalogen deficiency, including Rhizomelic chondrodysplasia punctata (RCDP).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Ppi-1011
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ppi-1011
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : BioPharma Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ppi-1011 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chondrodysplasia Punctata, Rhizomelic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2023
Lead Product(s) : Ppi-1011
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : BioPharma Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
